Review Article
Switching the Sphingolipid Rheostat in the Treatment of Diabetes and Cancer Comorbidity from a Problem to an Advantage
Table 1
Comparative selectivity of the S1P modulators (adapted from [88]).
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
+ indicates comparative selectivity of S1P modulators binding to individual receptors. |